Tengion Inc

Tengion — Investor Presentation (January 2014)

25 slides from Tengion's investor presentation, Jan 14, 2014

  1. Slide 1: Corporate Presentation January 2014

    Corporate Presentation January 2014

  2. Slide 2: Forward-looking statements

    Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to our future plans, objectives, expectations and intentions and may be identified by words like “believe,” “expect,”

  3. Slide 3: Investment Highlights

    Investment Highlights • Biotechnology company with unique technology platform for tissue and organ regeneration using a patient’s own cells • Neo-Kidney Augment: Intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease Tw

  4. Slide 4: Delivering Organ Regeneration for Patients

    Delivering Organ Regeneration for Patients Novel and proprietary technology platform: •Utilizes selected populations of regenerative cells •Potential to produce neo-organs at commercial scale •Potential for product line expansion Tissue biopsy Cell isolation and expansion Creation of product Implant

  5. Slide 5: Neo-Kidney Augment

    Neo-Kidney Augment

  6. Slide 6: Neo-Kidney Augment: Significant Market Opportunity

    Neo-Kidney Augment: Significant Market Opportunity •~26 million adults in U.S. have CKD 100,000 new dialysis patients each year 350,000 currently on dialysis 20% annual mortality $77,000 - annual cost per patient •Worldwide shortage of organs for transplant $100,000 - cost of transplant in U.S.

  7. Slide 7: Neo-Kidney Augment Development Process

    Neo-Kidney Augment Development Process Biopsy of kidney tissue Cell isolation and culture 2-3 weeks Cell selection <1 day Dose preparation 2 weeks Laparoscopic implantation

  8. Slide 8: Neo-Kidney Augment Overview

    Neo-Kidney Augment Overview •Intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced CKD •Robust preclinical data for Neo-Kidney Augment with defined mechanisms of action in CKD •Efficient and scalable manufacturing process •Ongoing clinical t

  9. Slide 9: Summary of Animal Study for NKA: End-point and Timelines

    Summary of Animal Study for NKA: End-point and Timelines* •NKA improved multiple systemic and histological measurements: Whole organism (Early effects ~ 3 months) Lowered mean arterial blood pressure Tubular & interstitial function (Early to Mid-term effects 3-6 months): Improved protein handlin

  10. Slide 10: Neo-Kidney Augment: Patient Expansion Planned in Sweden Phase 1 Trial

    Neo-Kidney Augment: Patient Expansion Planned in Sweden Phase 1 Trial •Phase 1 trial (Karolinska Institute in Stockholm, Sweden) Commenced in May 2013 5 patients implanted during 2013, planned expansion from 5 to 15 patients supported by DSMB Evaluate single pharmacologic dose and delivery in pat

  11. Slide 11: Neo-Kidney Augment: Phase 1 Trial Recently Initiated in U.S.

    Neo-Kidney Augment: Phase 1 Trial Recently Initiated in U.S. •Phase 1 trial in U.S. currently enrolling under an open IND Commenced in November 2013 Approved to enroll up to 12 patients Evaluate single pharmacologic dose and delivery in patients Will follow each patient for up to two years Anti

  12. Slide 12: Neo-Urinary Conduit

    Neo-Urinary Conduit

  13. Slide 13: Neo-Urinary Conduit: Large Market Opportunity

    Neo-Urinary Conduit: Large Market Opportunity Estimated Urinary Diversion Surgical Procedures in 2012 * 13,100 15,200 *L.E.K. and company estimates Number of procedures growing at ~3% per annum

  14. Slide 14: Standard-of-Care for Urinary Diversion

    Standard-of-Care for Urinary Diversion Bladder removed Section of bowel removed with blood supply maintained Bowel placed into urinary tract between ureters and abdominal wall Bowel connected to urine collection bag Standard-of-Care •Weeks to months of recovery time •Use of bowel creates absorption

  15. Slide 15: Neo-Urinary Conduit: Establish New Standard of Care for Cystectomy

    Neo-Urinary Conduit: Establish New Standard of Care for Cystectomy •Designed to establish new standard of care for bladder cancer patients undergoing cystectomy (removal of bladder) Eliminates need for bowel resection and urine absorption-related metabolic disorders 70% of patients receiving curre

  16. Slide 16: Advantages of Neo-Urinary Conduit

    Advantages of Neo-Urinary Conduit Neo-Urinary Conduit Bladder removed Conduit placed into urinary tract between ureters and abdominal wall Conduit connected to urine collection bag Advantages: •Improved recovery times and faster hospital discharges •No evidence to date of typical post-operative co-m

  17. Slide 17: Neo-Urinary Conduit: Surgery and Regenerative Outcome

    Neo-Urinary Conduit: Surgery and Regenerative Outcome •Implantation with ureters and skin •Regeneration of urinary tissue Ureters Urinary Conduit Urinary Tissue Omentum Implanted Neo-Urinary Conduit Regenerated Conduit Muco-Cutaneous Junction

  18. Slide 18: Neo-Urinary Conduit Phase 1 Clinical Trial

    Neo-Urinary Conduit Phase 1 Clinical Trial •Ongoing Phase 1 open-label study in up to 10 patients •Goals of Phase 1 trial: Define surgical procedure Transfer to multiple clinical sites Define post-operative procedures Demonstrate durable patient outcomes •Patient 7 now one year post-implant, pat

  19. Slide 19: Neo-Urinary Conduit Phase 1 Trial Progress

    Neo-Urinary Conduit Phase 1 Trial Progress: Defining Translation and Regeneration •Insights gained from 8 patients implanted to date: Surgical procedure for a NUC implantation demonstrates urinary tissue regeneration in patients with bladder cancer Established initial post-operative care to optimi

  20. Slide 20: Positive Initial Payer Comments

    Positive Initial Payer Comments •Believe $40,000 price for Neo-Urinary Conduit is reasonable •Incremental cost savings Reduction in hospitalization time Reduction in complications Quality of life improvements •Limited incremental exposure per payer •Older population likely covered by Medicare •Ot

  21. Slide 21: Corporate

    Corporate

  22. Slide 22: Significant IP Protection

    Significant IP Protection •Issued patent protection plus recent applications pending 28 U.S. and 97 international patents and patent applications Core patents cover composition, design and methods of manufacture* 8 issued and allowed patents in 2013 Plus know-how, trade secrets and integrated cap

  23. Slide 23: Financial Overview

    Financial Overview September 30, 2013 Cash and investments Principal amount of long-term debt Adjusted net loss $27.5 M $35.9 M $17.3 M December 31, 2012 $7.7 M $18.7 M $18.9 M $33.6M financing completed June 2013 Celgene Corporation RA Capital Deerfield Management Bay City Capital HealthCap Percept

  24. Slide 24: Investment Highlights

    Investment Highlights •Biotechnology company with unique technology platform for tissue and organ regeneration using a patient’s own cells •Neo-Kidney Augment: Intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease Two

  25. Slide 25: Corporate Presentation January 2014

    Corporate Presentation January 2014

Tengion — Investor Presentation (January 2014) on 6ix